Last reviewed · How we verify
Cyclorin (CYCLOSERINE)
Cycloserine (Cyclorin), marketed by Purdue Gmp, is an antibacterial agent indicated for active pulmonary tuberculosis, competing in a class with established drugs like rifampicin and rifabutin. Its key strength lies in its unique mechanism of action, which inhibits bacterial cell wall synthesis, offering an alternative for patients who may be resistant to other treatments. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | CYCLOSERINE |
|---|---|
| Sponsor | Purdue Gmp |
| Drug class | cycloserine |
| Target | Glutamate receptor ionotropic, NMDA 2A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1964 |
Approved indications
- Active Pulmonary Tuberculosis
- Active Extrapulmonary Tuberculosis
- Acute Urinary Tract Infections
Common side effects
- Convulsion
- Coma
- Major minor (localized) clonic seizures
- Cardiovascular: Sudden development of congestive heart failure
- Psychoses, possibly with suicidal tendencies
- Character changes
- Hyperirritability
- Aggression
- Paresis
- Hyperreflexia
- Paresthesia
- Drowsiness and somnolence
Key clinical trials
- A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder (PHASE1,PHASE2)
- AIH for Spinal Cord Repair (EARLY_PHASE1)
- Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine (PHASE2)
- D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT) (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression (PHASE2,PHASE3)
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province (NA)
- Effect of DCS on Post-Endodontic Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclorin CI brief — competitive landscape report
- Cyclorin updates RSS · CI watch RSS
- Purdue Gmp portfolio CI